An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)
Brief Summary
The primary objective of this study is to evaluate the efficacy of psilocybin (25 mg) administered under supportive conditions to adult participants with severe TRD, in improving depressive symptoms.
Study Design
| Study type: | Interventional |
|---|---|
| Status: | Recruiting |
| Study results: | No Results Available |
| Age: | 18 Years to 65 Years (Adult, Older Adult) |
| Enrollment: | 15 () |
| Funded by: | Other|Industry |
Masking |
|
Clinical Trial Dates
| Start date: | Mar 01, 2021 | |
|---|---|---|
| Primary Completion: | Apr 01, 2022 | |
| Completion Date: | Apr 01, 2022 | |
| Study First Posted: | Jun 16, 2020 | |
| Results First Posted: | Aug 30, 2020 | |
| Last Updated: | Dec 21, 2021 |
Sponsors / Collaborators
Lead Sponsor:
N/A
Responsible Party:
N/A
Eligibility Criteria
| Sex: | All |
|---|---|
| Minimum Age: | 18 |
| Maximum Age: | 65 |
This clinical trial is recruiting
Are you interested in participating in this trial or others? We'd love to help.
More Details
| NCT Number: | NCT04433858 |
|---|---|
| Other IDs: | 14947563 |
| Study URL: | https://ClinicalTrials.gov/show/NCT04433858 |
Last updated: Jun 16, 2022